LY2606368,
prexasertib,
Prexasertib,
LY2606368,
1234015-52-1,
UNII-820NH671E6,
LY-2606368,
820NH671E6,
5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile,
Prexasertib [USAN],
5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile,
5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile,
5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile,
LY2606368;Prexasertib,
GTPL9549,
SCHEMBL1975451,
CHEMBL3544911,
SCHEMBL18989301,
SCHEMBL19457660,
EX-A758,
DOTGPNHGTYJDEP-UHFFFAOYSA-N,
AOB87325,
BCP14380,
MFCD25977016,
ZINC95837013,
AKOS027427007,
CS-2198,
DB12008,
SB16662,
NCGC00390643-02,
BC600641,
HY-18174,
QC-11802,
FT-0700138,
LY 2606368;LY-2606368;Prexasertib,
J3.517.082K,
J-690088,
5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2- carbonitrile,
Sodium (2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl)phosphonate,
2-Pyrazinecarbonitrile, 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)-,
Prexasertib (LY2606368),
LY 2606368,
A13684,
5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile dihydrochloride,